Healthcare, Vol. 13, Pages 3102: Exploring Adults’ Experiences with Tirzepatide for Weight Loss: A Mixed-Methods Study
Healthcare, Vol. 13, Pages 3102: Exploring Adults’ Experiences with Tirzepatide for Weight Loss: A Mixed-Methods Study Healthcare doi: 10.3390/healthcare13233102 Authors: Shukri Adam Fatma M. Ibrahim Eman Abdelaziz Ahmed Dabou Sneha Pitre Rania Aiman Shimaa AbdelSamad Background: Obesity confers substantial cardiometabolic risk. Tirzepatide, a once-weekly dual GIP/GLP-1 receptor agonist, produces dose-dependent weight loss in trials, but […]
Nutrients, Vol. 17, Pages 3735: Beyond Weight Loss: GLP-1 Usage and Appetite Regulation in the Context of Eating Disorders and Psychosocial Processes
Nutrients, Vol. 17, Pages 3735: Beyond Weight Loss: GLP-1 Usage and Appetite Regulation in the Context of Eating Disorders and Psychosocial Processes Nutrients doi: 10.3390/nu17233735 Authors: Isabel Krug An Binh Dang Jade Portingale Yakun Li Ying Qing Won Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed treatment for higher weight and diabetes. Because they also […]
What we still don’t know about weight-loss drugs
Weight-loss drugs have been back in the news this week. First, we heard that Eli Lilly, the company behind the drugs Mounjaro and Zepbound, became the first healthcare company in the world to achieve a trillion-dollar valuation. Those two drugs, which are prescribed for diabetes and obesity respectively, are generating billions of dollars in revenue for […]
Comparative effectiveness of SGLT2 sodium‐glucose cotransporter‐2 inhibitors and GLP‐1 glucagon‐like peptide‐1 receptor agonists for incident dementia: A retrospective multicohort study
Abstract Objective This study provides real-world evidence on the comparative effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) regarding the risk of incident dementia in adults with type 2 diabetes mellitus (T2DM). Research Design and Methods This cohort study utilised electronic health records from TriNetX (1 April 2013 to 31 […]
Beauty Is Changing Its Game Plan for the Ozempic Era
From surgery to supplements, GLP-1 medications are radically evolving the beauty space. We unpack the latest innovations.
Opinion: Public health should embrace GLP-1 drugs without abandoning obesity prevention
Following the White House’s recent announcement of price reductions and expanded coverage for GLP-1 medications like Wegovy and Zepbound, many patients searching for obesity treatments are about to gain access to highly effective options. The implications for U.S. public health are vast. Read the rest…
Guggenheim Lifts PT on Pfizer Inc. (PFE) to $35 From $33, Keeps a Buy Rating
Pfizer Inc. (NYSE:PFE) is one of the best low volatility large cap stocks to invest in. On November 24, Guggenheim lifted the price target on Pfizer Inc. (NYSE:PFE) to $35 from $33 while keeping a Buy rating on the stock. The firm told investors that Pfizer Inc.’s (NYSE:PFE) acquisition of Metsera, Inc. marks a “a […]
**Breaking Down the Cost of Healthcare: Medicare Beneficiaries to Reap Benefits from Falling Drug Prices**
Breaking Down the Cost of Healthcare: Medicare Beneficiaries to Reap Benefits from Falling Drug Prices The rising cost of prescription medications has been a pressing concern for many Americans, particularly those relying on Medicare for their healthcare coverage. For years, the prices of certain medications have continued to soar, leaving many individuals struggling to afford […]
Amphastar (AMPH) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool. Date Saturday, Nov. 8, 2025 at 12:16 p.m. ET Call participants Chief Commercial Officer — Dan Dischner Chief Financial Officer and Executive Vice President of Finance — William Peters Senior Vice President, Regulatory Affairs and Clinical Operations — Tony Marrs Need a quote from a Motley Fool analyst? Email [email protected] […]
Cal-Maine Foods (CALM) Q1 2026 Earnings Transcript
Image source: The Motley Fool. DATE Wednesday, Oct. 1, 2025 at 12:22 p.m. ET CALL PARTICIPANTS President and CEO — Sherman Miller Chief Financial Officer — Max Bowman Need a quote from a Motley Fool analyst? Email [email protected] TAKEAWAYS Net Sales — $922.6 million, up 17.4%, driven by higher shell egg sales and prepared foods […]